Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Brain-protective treatments sits at the center of this dementia and brain health question.
Brain-protective treatments are reshaping dementia care by slowing cognitive decline in ways previously thought impossible. Two FDA-approved drugs—lecanemab, which reduces cognitive decline by 27% compared to placebo, and donanemab, which reduces disease progression by 36%—now offer people with early-stage Alzheimer’s disease a real way to buy time before symptoms become severe. Rather than simply managing symptoms once dementia takes hold, these treatments work upstream to target the physical changes in the brain that cause cognitive loss, fundamentally changing what doctors can offer patients in the earliest stages of disease. The impact is already showing in real-world practice.
A nationwide study tracking 289 million patients found that over 18 months, 3,402 people received anti-amyloid therapy, with the vast majority (3,242) using lecanemab. While this represents a small fraction of those who could benefit, it signals a shift: dementia care is moving toward prevention and early intervention rather than waiting for cognitive symptoms to progress. These treatments don’t cure dementia, and they come with tradeoffs—including the need for regular infusions, monitoring for brain inflammation, and significant cost. But for people facing early cognitive decline, brain-protective treatments offer something that hadn’t existed before: a medical option that genuinely slows the underlying disease process.
Table of Contents
- What Do Brain-Protective Treatments Actually Do to the Dementia Disease Process?
- How Will These Treatments Change What Patients and Families Experience?
- What Role Do These Treatments Play in a Broader Dementia Prevention and Care Strategy?
- What Are the Practical and Financial Barriers People Face When Accessing These Treatments?
- What Safety Concerns Should People Know About Before Starting Brain-Protective Treatments?
- What Emerging Approaches Are Being Developed to Improve Brain Protection?
- What Does the Future of Brain-Protective Dementia Care Look Like?
- Conclusion
- Frequently Asked Questions
What Do Brain-Protective Treatments Actually Do to the Dementia Disease Process?
Brain-protective treatments target amyloid-beta, a protein that accumulates in the brains of people with Alzheimer’s disease, triggering inflammation and neuronal death. Lecanemab and donanemab work by labeling these amyloid clumps so the body’s immune system can clear them away. This is mechanistically different from older Alzheimer’s medications like donepezil, which simply help existing brain cells communicate better—they don’t address the root cause of cognitive decline. The clinical trial results tell a concrete story. In the lecanemab trials, people who received the drug showed a 27% slowing of cognitive decline over 18 months compared to those who received placebo.
Donanemab performed even better, with a 36% reduction in disease progression, though the study population was slightly earlier in disease stages. To put this in practical terms: if someone receiving placebo might decline from a score of 24 to 16 on cognitive testing over 18 months, someone on lecanemab might decline from 24 to 18—a meaningful but not dramatic difference. A crucial limitation: these treatments work best when started early, before extensive brain damage has occurred. A recent analysis estimated that amyloid-targeting drugs could delay the onset of severe dementia by anywhere from 4 to 7 months in a conservative scenario, 1.1 to 1.9 years in an intermediate scenario, or 2.0 to 4.2 years in an optimistic scenario, depending on when treatment starts and individual variability. This means the window for benefit is the early symptomatic stages—mild cognitive impairment or mild dementia—not advanced disease.
How Will These Treatments Change What Patients and Families Experience?
For many families, the emotional weight of an Alzheimer’s diagnosis comes from watching someone you love gradually fade. Brain-protective treatments offer the possibility of slowing that process, which can change the entire trajectory of a family’s experience. Instead of rapid decline that moves someone from independent living to full care within a few years, these treatments might extend the period where someone remains cognitively functional by months or years. But this shift brings new complexity. Because these treatments require regular IV infusions—typically every 2 to 4 weeks—they introduce a medical burden into daily life that older Alzheimer’s medications did not.
patients need regular MRI scans to monitor for amyloid-related imaging abnormalities (ARIA), a form of brain inflammation that can cause headaches, confusion, or cognitive changes. Most people tolerate this well, but approximately 10-15% of people on lecanemab developed clinically significant brain inflammation. This means brain-protective treatment isn’t a simple pill to take at home; it’s an active medical intervention requiring clinical monitoring, which can be challenging for rural patients or those with limited access to specialized centers. There’s also a psychological component worth acknowledging: slowing decline is not the same as stabilizing or reversing cognitive loss. People on these drugs still experience some cognitive decline; it’s just slower. Managing expectations about what “slowing decline” means—preventing the loss of one year of cognitive function, not returning to baseline—becomes important work for clinicians and families to do together.
What Role Do These Treatments Play in a Broader Dementia Prevention and Care Strategy?
Brain-protective treatments are one piece of a larger puzzle that now includes preventive interventions, lifestyle factors, and emerging technologies. A major 20-year study published in early 2026 showed that adults over 65 who completed just 5 to 6 weeks of adaptive “speed of processing” brain training—exercises that improve visual attention and decision-making speed—had a 25% lower risk of developing dementia compared to controls who received no training. This finding is significant because it suggests that cognitive intervention, even simple computerized training, can meaningfully reduce dementia risk. The real opportunity lies in combining these approaches. Someone at high risk for dementia might benefit from brain training and other preventive strategies like cardiovascular exercise, cognitive engagement, and sleep optimization long before they develop symptoms.
Once mild cognitive changes appear, they become a candidate for amyloid screening (via blood tests or PET imaging) and potentially for brain-protective drugs if amyloid is present. This creates a continuum of care rather than a single intervention. The timeline matters. Brain-protective treatments appear most effective when someone still has substantial cognitive reserve—the ability to compensate for some brain damage through other neural pathways. Someone in advanced dementia, having lost significant brain tissue and cognitive capacity, is unlikely to benefit from amyloid clearance alone. This is why identifying people in the early stages is so important, and why public health efforts around cognitive screening and amyloid testing in primary care settings are emerging.
What Are the Practical and Financial Barriers People Face When Accessing These Treatments?
Cost is a barrier that cannot be overlooked. Lecanemab infusions cost around $26,500 per year, and Medicare now covers it for beneficiaries meeting eligibility criteria, but coverage decisions vary by insurance plan and geography. Donanemab, newly approved, may face similar cost barriers. For people without insurance or those in states that haven’t expanded Medicaid coverage, access remains out of reach. Beyond cost, there are logistical challenges.
Regular infusions require transportation to a specialized center—not every community has an infusion center that can administer these drugs. Rural patients, those with mobility limitations, or those without reliable transportation face significant barriers. The screening process itself—determining who has amyloid pathology and would benefit from treatment—requires either blood biomarker testing (which is increasingly available but not yet universally covered) or PET imaging (which is expensive and still limited in availability outside major medical centers). A practical example: A 72-year-old woman living in a rural area with mild cognitive impairment might benefit from lecanemab, but to access it, she’d need to travel 90 minutes each way to an infusion center every 2 weeks, arrange care coverage during those trips, navigate insurance approvals, and potentially pay out-of-pocket costs. These practical barriers often mean that people who could benefit most—those in early stages—are the ones least likely to receive these treatments if they live in underserved areas.
What Safety Concerns Should People Know About Before Starting Brain-Protective Treatments?
Amyloid-related imaging abnormalities (ARIA) are the primary safety concern with amyloid-targeting monoclonal antibodies. ARIA appears in two forms: microhemorrhages (tiny bleeds in the brain) and microinfarcts (small areas of dead brain tissue). Most people with ARIA imaging abnormalities are asymptomatic and experience no clinical problems. However, symptomatic ARIA can cause headaches, confusion, behavioral changes, or cognitive decline, and requires immediate medical attention. The risk of symptomatic ARIA increases in people carrying the APOE4 gene variant, especially those with two copies of this gene.
This genetic susceptibility means that before starting these treatments, genetic testing or careful clinical assessment should occur. Someone with APOE4/APOE4 genotype might show ARIA on imaging in 15-20% of cases, compared to lower rates in people without this genetic risk factor. This doesn’t mean APOE4 carriers shouldn’t receive these treatments, but it does mean they need more intensive brain imaging monitoring and should be counseled about this increased risk. Another limitation: these treatments don’t address non-amyloid forms of dementia. Frontotemporal dementia, vascular dementia, and Lewy body dementia involve different disease processes and won’t respond to amyloid-targeting drugs. Accurate diagnostic workup to confirm amyloid pathology is essential, which means not everyone with cognitive decline is a candidate for these treatments, even if they’re available and affordable.
What Emerging Approaches Are Being Developed to Improve Brain Protection?
Beyond the currently approved drugs, researchers are developing new technologies aimed at improving brain health and amyloid clearance. Nanotechnology treatments are under development to create more efficient ways to clear amyloid-beta and restore healthier blood vessel activity in the brain—potentially offering treatments that work faster or with fewer side effects than current monoclonal antibodies. These approaches are still in earlier stages but represent the direction of the field.
One novel intervention already in clinical use for early Alzheimer’s is Cognito Therapeutics’ SPECTRIS headset, which uses flickering lights and synchronized sounds to stimulate the brain’s visual cortex and gamma wave activity. The theory is that this stimulation enhances the brain’s natural ability to clear amyloid. While results are still being evaluated, this represents a completely different category of brain-protective intervention—non-pharmacological, non-invasive, and potentially accessible in home settings. The advantage over infusions is clear: patients could use it at home without transportation barriers or medical monitoring burdens.
What Does the Future of Brain-Protective Dementia Care Look Like?
The landscape of dementia care is rapidly evolving toward earlier detection and prevention. In the near term, expect brain-protective treatments to become more integrated into mainstream neurology and geriatric practice as clinical experience accumulates and more data emerges about long-term outcomes. The current data shows benefit over 18 to 21 months; what happens after 3 to 5 years of treatment is still being learned from real-world use.
Looking forward, the most exciting possibility is a prevention-focused approach where brain-protective treatments are offered not just to people with symptoms, but to cognitively normal people with high amyloid burden who are destined to develop dementia. Some research is already moving in this direction, with trials testing whether early amyloid-targeting treatment in asymptomatic individuals can prevent cognitive decline entirely. If these prevention trials succeed, dementia care could shift from treating disease after it appears to preventing it before symptoms start—a fundamental transformation in how we approach brain aging.
Conclusion
Brain-protective treatments represent a genuine advance in dementia care by offering an intervention that slows the underlying disease process rather than simply masking symptoms. Lecanemab and donanemab provide meaningful, measurable benefits for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease, potentially extending the years of cognitive independence and reducing the pace of decline. These drugs work best as part of a broader strategy that includes preventive interventions, early detection, and comprehensive care planning.
However, access to these treatments remains limited by cost, geography, infrastructure, and the need for specialized diagnostic testing and monitoring. For brain-protective treatments to truly transform dementia care, addressing these barriers is essential. At the same time, people and families should understand that “slowing decline” is not the same as cure or reversal, and that these treatments work best in the early stages of disease when preventive strategies and lifestyle interventions may also help preserve brain health. The future of dementia care likely lies not in any single treatment, but in combining brain-protective drugs, cognitive interventions, lifestyle modification, and earlier detection—creating a multi-pronged approach to protecting the aging brain.
Frequently Asked Questions
Am I a candidate for lecanemab or donanemab?
You may be a candidate if you have been diagnosed with mild cognitive impairment or mild dementia due to Alzheimer’s disease, have been found to have amyloid pathology in your brain (via blood tests, PET imaging, or cerebrospinal fluid testing), and are generally healthy enough to tolerate regular IV infusions and MRI monitoring. Your doctor can determine eligibility based on your specific situation.
How often do I need infusions, and how long do they take?
Lecanemab is given as an IV infusion every 2 weeks (after an initial ramp-up phase), and each infusion takes about 1 hour. Donanemab uses a less frequent dosing schedule. Both require regular scheduling and transportation to an infusion center.
What happens if I develop ARIA (amyloid-related imaging abnormalities)?
Most people with ARIA on brain imaging have no symptoms and continue treatment safely with regular monitoring. If you develop symptoms (headaches, confusion, cognitive changes), you need immediate medical evaluation and may need to pause or stop treatment. Your doctor will determine the best course of action.
Can these treatments prevent dementia if I don’t have symptoms yet?
Current FDA approvals are for people with mild cognitive impairment or mild dementia. However, research trials are ongoing to test whether these treatments can prevent cognitive decline in cognitively normal people with high amyloid burden. Talk with your doctor about whether you might be eligible for a clinical trial.
Do these drugs work for all types of dementia?
No. These amyloid-targeting treatments are designed for Alzheimer’s disease, which accounts for 60-80% of dementia cases. They do not treat frontotemporal dementia, vascular dementia, Lewy body dementia, or other non-amyloid dementias. Accurate diagnosis is essential.
What’s the difference between lecanemab and donanemab?
Both target amyloid, but donanemab showed a higher percentage reduction in disease progression (36% vs. 27%) in clinical trials and may be dosed less frequently. Both work best in early disease stages. Your doctor can help determine which might be appropriate based on your individual situation, disease stage, and other factors.
You Might Also Like
- What CNS-3D Models Could Mean for Dementia Research
- How Predictive Models Could Improve Dementia Therapy Testing
- How Advanced Imaging May Lead to New Dementia Treatments
For more, see Alzheimer’s Association.
